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Abstract
Introduction The function of the vascular endothelial growth
factor (VEGF) system in acute lung injury (ALI) is controversial.
We hypothesized that the role of VEGF in ALI may depend upon
the stages of pathogenesis of ALI.
Methods To determine the responses of VEGF and its
receptors during the early onset of ALI, C57BL6 mice were
subjected to intestinal ischemia or sham operation for 30
minutes followed by intestinal ischemia-reperfusion (IIR) for four
hours under low tidal volume ventilation with 100% oxygen. The
severity of lung injury, expression of VEGF and its receptors
were assessed. To further determine the role of VEGF and its
type I receptor in lung epithelial cell survival, human lung
epithelial A549 cells were treated with small interference RNA
(siRNA) to selectively silence related genes.
Results IIR-induced ALI featured interstitial inflammation,
enhancement of pulmonary vascular permeability, increase of
total cells and neutrophils in the bronchoalveolar lavage (BAL),
and alveolar epithelial cell death. In the BAL, VEGF was
significantly increased in both sham and IIR groups, while the
VEGF and VEGF receptor (VEGFR)-1 in the lung tissues were
significantly reduced in these two groups. The increase of VEGF
in the BAL was correlated with the total protein concentration
and cell count. Significant negative correlations were observed
between the number of VEGF or VEGFR-1 positive cells, and
epithelial cells undergoing cell death. When human lung
epithelial A549 cells were pre-treated with 50 nM of siRNA
either against VEGF or VEGFR-1 for 24 hours, reduced VEGF
and VEGFR-1 levels were associated with reduced cell viability.
Conclusion These results suggest that VEGF may have dual
roles in ALI: early release of VEGF may increase pulmonary
vascular permeability; reduced expression of VEGF and
VEGFR-1 in lung tissue may contribute to the death of alveolar
epithelial cells.
Introduction
Acute lung injury (ALI) along with its severe form, acute respi-
ratory distress syndrome (ARDS), is one of the most challeng-
ing conditions in critical care medicine. ALI/ARDS can result
from a direct insult in the lung or an indirect insult from other
organs mediated through the systemic circulation [1,2]. ARDS
of both etiologies results in acute inflammatory responses
leading to lung dysfunction [3]. Mesenteric ischemia-reper-
fusion represents an important cause of extrapulmonary
ARDS, as gut mucosal perfusion deficits appear to be instru-
mental in the propagation of multiple organ failure, of which the
most vulnerable organ is the lung [4].
Increased pulmonary permeability that leads to diffuse intersti-
tial and pulmonary edema is one of the most important mani-
festations of ALI/ARDS [5]. Increased cell death has been
proposed to be an important component for lung tissue dam-
age [6]. Vascular endothelial growth factor (VEGF) and its
ALI = acute lung injury; ARDS = acute respiratory distress syndrome; BAL = bronchoalveolar lavage; EBD = Evans Blue Dye; FITC = fluorescein 
isothiocyanate; GAPDH = glyceraldehyde-3-phosphate dehydrogenase; IHC = immunohistochemistry; IIR = intestinal ischemia-reperfusion; MV = 
mechanical ventilation; PBS = phosphate-buffered saline; RT-PCR = reverse transcriptase PCR; siRNA = small interference RNA; TMR = tetrame-
thylrhodamine; TUNEL = terminal transferase dUTP nick end labeling; VEGF = vascular endothelial growth factor; VEGFR = vascular endothelial 
growth factor receptor.Critical Care    Vol 10 No 5    Mura et al.
Page 2 of 13
(page number not for citation purposes)
receptors are critical in the regulation of both vascular perme-
ability and endothelial cell survival. Therefore, VEGF and
related molecules may have important roles in the develop-
ment of ALI/ARDS [7].
The VEGF system consists of several VEGF isoforms and
VEGF receptors (VEGFRs). Most studies have focused on
VEGF-A (from hereon the abbreviation VEGF refers to VEGF-
A) because it plays an essential role in angiogenesis and vas-
cular permeability [8,9]. In the lung tissue, VEGF is highly com-
partmentalized and mainly produced in epithelial cells,
whereas endothelial cells are suggested as its major target
[10,11]. Most of the angiogenic activities of VEGF as well as
its effects on vascular permeability are mediated by its recep-
tor Flk-1 (VEGFR-2) [12], while the functions of Flt-1 (VEGFR-
1), especially its role in ALI, are largely unknown.
Pulmonary permeability is controlled by both endothelial and
epithelial layers. Pulmonary injury in ARDS causes widespread
destruction on both sides of the epithelial-endothelial barrier
[5,13]. The effect of VEGF on endothelial cell permeability and
survival has been demonstrated in both in vitro and in vivo
studies [14,15]. The effect of the VEGF system on the integrity
of pulmonary epithelium is unclear.
VEGF may contribute to the development of noncardiogenic
pulmonary edema in ALI/ARDS [16]. Systemic overexpression
of VEGF has been shown to cause widespread capillary leak-
age in multiple organs [9], and high plasma levels of VEGF
were found in ARDS patients [16]. However, studies from ani-
mal models as well as from ARDS patients have shown that
decreased levels of VEGF in the lung are associated with a
worse prognosis [17-19]. Therefore, the role of VEGF and
related molecules in ALI/ARDS is controversial [7]. One pos-
sible explanation is that VEGF may play different roles at differ-
ent stages of the development of and recovery from ALI/ARDS
[7]. We hypothesized that, in the early stage of lung injury, the
release of VEGF from alveolar epithelial cells and leukocytes
induced by acute inflammatory response may increase the vas-
cular permeability and contribute to the formation of interstitial
edema in the lung, whereas reduced VEGF and its receptors
in alveolar epithelial cells due to tissue damage may lead to
cell death. In the present study, we investigated the release of
VEGF, and the expression and distribution of VEGF and its
receptors in the lung during the early onset of ALI induced by
intestinal ischemia-reperfusion (IIR), a well-established model
of extrapulmonary ARDS [20,21]. Since expression levels of
VEGF and VEGFR-1 were negatively correlated with alveolar
epithelial cell death, we investigated the potential roles of
these two proteins on epithelial survival by reducing their
expression with small interference RNA (siRNA) in A549 cells,
a human lung epithelial cell line with partial type II pneumocyte
characteristics.
Materials and methods
Intestinal ischemia-reperfusion model in mice
We randomized 6 to 9 week old male C57BL6 mice (weight
= 25.8 ± 2.7 g) into IIR, sham (sham-operated), or control
groups. The animals subjected to IIR or sham operation were
anesthetized with an intraperitoneal injection of acepromazine
(10 mg/ml)-ketamine (100 mg/ml) (10:1, 0.15 ml). Tracheos-
tomy was performed after blunt dissection of the neck and
exposure of the trachea. A metal cannula for mouse (1.0 mm;
Harvard Apparatus, St Laurent, Canada) was inserted into the
trachea, and animals were connected to a volume-controlled
constant flow ventilator (Inspira Advanced Safety Ventilator,
Harvard Apparatus). Anesthesia was continuously maintained
with isoflurane and body temperature was maintained at 37°C
by an immersion thermostat throughout the experiment. In the
IIR group the abdomen was rinsed with betadine, a lower mid-
line laparatomy was performed and the superior mesenteric
artery was identified and occluded below the celiac trunk with
an arterial microclamp. Intestinal ischemia was confirmed by
paleness of the jejunum and ileum. After 30 minutes the clamp
was removed, 0.5 ml of sterile saline at 37°C was injected into
the peritoneal cavity and the skin was sutured. The same pro-
cedures were carried out in the sham group, but the
mesenteric artery was not clamped. The animals were then
ventilated for four hours with a tidal volume of 6 ml/kg, inspira-
tory oxygen fraction 1.0, inspiratory/expiratory ratio 1:2 and a
frequency of 140 breaths per minute. An esophageal catheter
(Harvard Apparatus) was applied to eight animals per group
for measurement of dynamic lung compliance. The left femoral
artery was cannulated in four animals per group for measure-
ment of mean arterial blood pressure. Airways pressures,
dynamic lung compliance and blood pressure were continu-
ously monitored throughout the four hour period of mechanical
ventilation (MV) with HSE-USB acquisition hardware and Pul-
modyn software (H Sachs Elektronik, March-Hugstetten, Ger-
many). The control group consisted of mice spontaneously
breathing room air. The experimental protocol was approved
by the Toronto General Hospital Animal Care and Use Com-
mittee. All mice received care in compliance with the Princi-
ples of Laboratory Animal Care formulated by the National
Society for Medical Research, and the Guide for the Care and
Use of Experimental Animals formulated by the Canadian
Council on Animal Care.
All animals were sacrificed by exsanguinations. The lungs
were sub-grouped either for histological evaluation and immu-
nohistochemistry (n  = 4/group) or bronchoalveolar lavage
(BAL; n = 12/group). Blood samples were collected (n = 8
animals/group) at the end of the experiment by puncture of the
aorta. After centrifugation at 4,000 g for 10 minutes, plasma
samples were stored at -20°C before use.
Assessment of acute lung injury
Lungs for histological evaluation were removed en bloc and
inflated at a 20 cm height with 4% paraformaldehyde in PBSAvailable online http://ccforum.com/content/10/5/R130
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for fixation. Sections (4 µm) were either stained with haema-
toxylin and eosin or processed for immunohistochemistry. A
pulmonary pathologist performed the histological analysis in a
blinded fashion. The degree of lung injury was determined
using the grading system developed by Ginsberg and col-
leagues [22].
BAL was performed by instilling 0.5 ml of saline through the
endotracheal tube and gently aspirating back. This was
repeated twice and the amount of fluid recovered was
recorded. An aliquot of BAL fluid (50 µl) was diluted 1:1 with
trypan blue for total cell counting using a haemocytometer. In
8 animals per group, an aliquot of BAL fluid (80 µl) underwent
cytospin (72 g, 5 minutes) and the cells collected were stained
using the Harleco Hemacolor staining kit (EMD Science,
Gibbstown, NJ, USA). Differential cell count was conducted
by counting of at least 500 cells. The remainder of the lavage
fluid was centrifuged (4,000 g, 10 minutes), and the superna-
tant was stored at -20°C until measurement of protein concen-
tration with Bradford assay (Bio-Rad Laboratories, Hercules,
CA, USA).
For the Evans Blue Dye (EBD) permeability assay, the left jug-
ular vein was isolated and cannulated in four animals per
group. An EBD solution (5 mg/ml) was injected into the left
jugular vein (30 mg/kg) 30 minutes prior to sacrifice of the ani-
mal. The BAL fluid and plasma were collected and the optical
density of EBD was read at 630 nm with a spectrophotometer
(Opsys MR, Thermo Labsystems, Franklin, MA, USA). The
optical density ratio of BAL/plasma EBD was then calculated.
Enzyme-linked immunosorbent assay
VEGF levels were determined in the BAL supernatants and
plasma samples using an ELISA kit (DuoSet Mouse VEGF,
R&D Systems, Minneapolis, MN, USA) that recognizes VEGF
isoforms with either 120 or 164 amino acids. Assays were per-
formed in duplicate following the manufacturer's instructions.
Immunohistochemistry
For immunohistochemistry (IHC), lung tissue slides (4 µm)
were pre-treated with 0.25% Triton X-100 for five minutes and
blocked for endogenous peroxidase and biotin with 0.3%
H2O2 in methanol. The slides were incubated with designated
primary antibodies, with a dilution of 1:200 for VEGF (sc-507),
1:20 for VEGFR-1 (sc-316) and VEGFR-2 (sc-505) from
Santa Cruz Biotechnology (Santa Cruz, CA, USA), for 32 min-
utes at 42°C, and then with a secondary antibody (1:600) for
20 minutes. Detection was done by Avidin Biotin Complex sys-
tem with 3–3 diaminobenzidine as chromogen from a VECT-
STAIN ABC kit (PK-4001, Vector Laboratories, Burlingame,
CA, USA). Cell nuclei were counterstained with hematoxylin.
Non-immune serum instead of the primary antibody was used
for negative controls (data not shown). The VEGFR-1 staining
was abolished by pre-incubation of slides with a specific
blocking peptide (sc-316p, Santa Cruz) (data not shown).
For quantitative analysis, 10 optical fields of alveolar area from
each animal (4 mice/group), not including major airways or
vessels, were randomly chosen at 1,000 × magnification. The
numbers of cells with VEGF, VEGFR-1 or VEGFR-2 positive-
staining as well as the total cell nuclei in the chosen fields were
counted, respectively, in a double blind fashion. The number of
positive-stained cells was expressed as a percentage of the
total cells. The staining intensities in bronchial epithelium (cili-
ated or non-ciliated cells), alveolar epithelium (type I and type
II cells), interstitial cells, vascular endothelium and alveolar
macrophages were also scored semi-quantitatively [23]. Dif-
ferent cell types were identified by their location and morphol-
ogy. This screening test could provide an overall impression of
the changes of VEGF and its receptors in different cell types.
TUNEL-cytokeratin double fluorescent staining
Terminal transferase dUTP nick end labeling (TUNEL) staining
(In Situ Cell Death Detection Kit, TMR Red, Roche, Penzberg,
Germany) was used to assess cell death in the lung tissues
after deparaffinization, dehydration and permeabilization with
Table 1
Survival, physiological and lung injury parameters.
N Control Sham IIR
Survival (percent) 24 NA 100 50a
Blood pressure after 4 h (mmHg) 4 NA 51.0 ± 6.1 32.5 ± 10.3a
BAL protein concentration (µg/ml) 12 46.1 ± 30.7 149.2 ± 72.0b 174.4 ± 82.2c
BAL total cell count (× 105/ml) 12 6.8 ± 3.2 11.4 ± 2.1b 16.8 ± 7.2a, c
BAL neutrophils (percent) 8 4.8 ± 3.6 4.6 ± 3.9 18.5 ± 13.0d
EBD permeability assay 4 0.021 ± 0.00 0.024 ± 0.01 0.038 ± 0.00d
Compliance percentage of 
decrease from baseline)
8 NA 0.2 ± 0.0 18.8 ± 8.8a
ap < 0.05 versus sham; bp < 0.05 and cp < 0.01 versus control; dp < 0.05 versus other groups. BAL, bronchoalveolar lavage; EBD, Evans Blue 
Dye; IIR, intestinal ischemia-reperfusion; NA, not applicable.Critical Care    Vol 10 No 5    Mura et al.
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10 µg/ml proteinase K in 10 mM Tris/HCl, pH 7.4–8, for 15
minutes. The slides were then stained for cytokeratin by incu-
bating with an anti-cytokeratin-18 monoclonal antibody (1:25,
Chemicon, Temecula, CA, USA) at 4°C overnight, and with a
fluorescent-FITC-conjugated  goat anti-mouse IgG (1:500,
Biotium, Hayward, CA, USA) at room temperature for 1 h.
Label solution without terminal transferase for TUNEL or non-
immune serum was used as negative controls. Tetramethyl-
rhodamine (TMR)-labeled TUNEL-positive nucleotides and
FITC-labeled cytokeratin-positive epithelial cells were
detected under fluorescence microscope. Ten fields were ran-
domly chosen from each animal (4 mice/group) at 1,000 ×
magnification and each field contained approximately the
same number of alveoli without major airways or vessels. The
number of TUNEL-cytokeratin double positive cells and the
total cytokeratin positive cells per optical field were quantified.
An epithelial cell death index for each animal was calculated
as: (TUNEL-cytokeratin positive cells/cytokeratin positive
cells) × 100%.
Western blotting
The protocols for sample preparation and western blotting of
lung tissue lysate have been previously described [24-27].
The protein concentration from homogenized snap-frozen lung
samples (four from each group) was determined by the Brad-
ford method. Equal amounts of protein from each sample were
boiled in SDS sample buffer and subjected to SDS-PAGE.
Proteins were transferred to nitrocellulose membranes. Non-
specific binding was blocked by incubation of membranes
with 5% (w/v) nonfat milk in PBS for 60 minutes. Blots were
incubated with the designated antibody (VEGF sc-507,
VEGFR-1 sc-316, or VEGFR-2 sc-6251 antibodies, Santa
Cruz Biotechnology) at 1:1,000 dilution overnight at 4°C. The
blots were then washed with PBS-0.05% Tween 20 and incu-
bated for 60 minutes at room temperature with horseradish
peroxidase-conjugated goat anti-rabbit (1:30,000 dilution) or
anti-mouse (1:20,000 dilution) IgG (both from Amersham,
Oakville, Canada). After washing, blots were visualized with an
enhanced chemiluminescence detection kit (Amersham). We
stripped and reprobed blots with antibody for glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) as a housekeeping
control. Autoradiographs were quantified using a densitome-
ter (GS-690; Bio-Rad Laboratories) and normalized to the
GAPDH control.
Real-time RT-PCR
Quantitative real-time reverse transcriptase PCR (RT-PCR)
analysis of the RNA expression of VEGF, VEGFR-1 and
VEGFR-2 was performed on RNA isolated from frozen lung tis-
sues (four animals/group) as previously described [28]. The
primer sequences are available upon request.
Figure 1
Intestinal ischemia reperfusion (IIR)-induced acute lung injury Intestinal ischemia reperfusion (IIR)-induced acute lung injury. (a) In comparison with control group, lung histology (haematoxylin and eosin, magnifi-
cation 400×) shows a minor infiltration of leukocytes in the sham group. In the IIR group, a diffuse increase of interstitial cellularity, with both mono-
nuclear cells and neutrophil infiltration, interstitial edema, and vascular congestion were observed. Slides shown are representatives of four animals 
from each group. (b) The severity of lung tissue injury in each group was quantitatively scored; *p < 0.05 versus control and sham groups.Available online http://ccforum.com/content/10/5/R130
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VEGF and VEGFR-1 knock-down with siRNA in A549 
cells
A549 cells were cultured in DMEM with 10% fetal bovine
serum to about 50% confluence in 24-well plates, and then
treated with 50 nM of siRNA against either VEGF (M-003550)
or VEGFR-1 (M-003136) mRNA, or a non-specific duplex
RNA (D-001206-13-05) as negative control (SMARTpool,
Upstate, Charlottesville, VA, USA) using oligofectamine as
transfection reagent (Invitrogen, Carlsbad, CA, USA). At 24 h
after transfection, cell morphology was examined with phase-
contrast microscopy, and cell viability was determined with an
XTT assay following the manufacturer's instructions (Roche).
The knock-down effect at the protein level in the cells was
determined by immunofluorescent staining and western blot-
ting with polyclonal antibodies against VEGF or VEGFR-1
(Santa Cruz), respectively. The immunoflurescent staining was
visualized with a TMR-conjugated anti-rabbit IgG (1:400) as
the secondary antibody. The protocol for immunofluorescent
staining has been previously described in detail [28-30].
Statistical analyses
All data are expressed as mean ± standard deviation and were
analyzed with JMP software (SAS Institute, Cary, NC, USA).
Distribution analysis was performed to test skewing for all var-
iables. The non-parametric Kruskal-Wallis (two-tailed) test was
used for comparison of multiple groups, followed by the
Dunn's test for comparisons between individual groups. Cor-
relation studies were performed with Spearman rank correla-
tion (Rho factor). P values less than 0.05 are regarded as
significant.
Figure 2
Intestinal ischemia reperfusion (IIR)-induced changes in vascular endothelial growth factor (VEGF) expression in the lung Intestinal ischemia reperfusion (IIR)-induced changes in vascular endothelial growth factor (VEGF) expression in the lung. (a) VEGF in the broncho-
alveolar lavage (BAL) fluid (n = 12/group); *p < 0.05 compared with the control. (b) VEGF in the plasma (n = 8/group). (c) VEGF immunostaining in 
the lung tissues (n = 4/group). Slides shown are representatives for each group (magnification 1,000×), and arrowheads indicate the examples of 
positive stained cells (in brown). (d) Quantification of VEGF positive cells per field. Ten fields were counted from each animal and four animals from 
each group. In the IIR group, the number and intensity of positive stained cells in the alveolar walls were remarkably decreased. **p < 0.01 compared 
with the control group; #p < 0.05 compared with the sham group.Critical Care    Vol 10 No 5    Mura et al.
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Results
Intestinal ischemia-reperfusion-induced acute lung 
injury
Animals in the IIR group developed ALI. The overall survival
was 50% in the IIR group, while no mortality was observed in
the sham group within the 4 h experimental period. The distrib-
utive shock following the release of proinflammatory mediators
from the injured intestine may be the cause of this high rate of
mortality, as the blood pressure in the IIR group decreased sig-
nificantly, in comparison with that in the sham group (Table 1).
The mean blood pressure in the sham group was similar to that
described in mechanically ventilated C57BL6 mice under
anesthesia [31].
The total cell number in the BAL was significantly increased in
the IIR group, compared with that in the sham (p < 0.05) and
control (p < 0.01) groups. The differential cell count showed a
significantly higher percentage of neutrophils in the IIR group.
A significant increase of total cell counts and protein concen-
tration was also observed in the BAL from the sham group
compared to that of control animals, which may be due to the
high concentration of oxygen used for ventilation. However,
when EBD assay was used to further assess the pulmonary
permeability, a significant increase in the BAL/plasma EBD
ratio was only detected in the IIR group (Table 1). After 4 h of
reperfusion, the lung compliance did not significantly change
in the sham group, whereas it was significantly decreased in
the IIR group, in comparison with the basal line (p < 0.05;
Table 1).
The histological studies showed a minimal and focused
increase of interstitial cellularity in the sham group and a dif-
fuse increase, due to infiltration of both mononuclear cells and
neutrophils, in the IIR group (Figure 1a). Diffuse interstitial
edema and vascular congestion were observed in the IIR
group (Figure 1a). These features are compatible with those
observed in early extrapulmonary ARDS [3]. As a result, the
lung injury score was significantly increased in the IIR group
(Figure 1b).
VEGF increased in the BAL but decreased in the lung 
tissues after IIR
We then investigated the alterations of VEGF and its recep-
tors in IIR-induced ALI. A significant increase of VEGF in the
BAL fluid was found from both the sham and IIR groups (Fig-
ure 2a), while no difference in the plasma levels of VEGF was
found among the groups (Figure 2b).
The expression and distribution of VEGF in the lung tissues
were examined with IHC. VEGF expression in control and
sham-operated animals was characterized by strong staining
of bronchial epithelial cells and moderate to diffuse staining of
vascular endothelial cells (Table 2). Type II epithelial cells and
occasional alveolar macrophages were VEGF-positive (Figure
2c, Table 2). In the IIR group, the intensity and the number of
VEGF-positive cells were clearly decreased, especially in alve-
olar epithelial cells and bronchial epithelial cells (Figure 2c,
Table 2). The percentage of identifiable VEGF-positive cells in
the alveolar walls was quantified in a double-blinded fashion
and expressed as a percentage of the total number of cells in
each field, which was significantly lower in the IIR group (Fig-
ure 2d).
Decreased VEGFR-1 expression in the injured lung 
tissues
Strong staining of both airway and alveolar epithelial cells
characterized the VEGFR-1 distribution in the control group
(Table 2, Figure 3a). In the sham group, a similar staining pat-
tern was observed, with much fewer positive cells in the alve-
olar units (p < 0.05). The decrease of VEGFR-1 positive cells
was more significant in the IIR group (p < 0.01), due to the
reduced staining on type I epithelial cells, interstitial cells and
alveolar macrophages (Figure 3, Table 2).
Table 2
Differential patterns of VEGF and VEGFRs immunostaining in the lung cells.
VEGF VEGFR-1 VEGFR-2
Control Sham IIR Control Sham IIR Control Sham IIR
Bronchial epithelium (ciliated) +++ +++ ++ +++ +++ ++ ++ ++ ++
Bronchial epithelium (non-
ciliated)
+++ +++ ++ ++ ++ ++ ++ ++ ++
Type I cells + + - ++ + + - - -
Type II cells ++ ++ + +++ ++ + + ++ ++
Interstitial cells - - - ++ + + - - -
Vascular endothelium ++ ++ ++ +++ +++ ++ + + +
A l v e o l a r  m a c r o p h a g e s +++ + + +++++
Unstained, -; occasional staining, +; weak to moderate diffuse staining, ++; strong diffuse staining, +++. IIR, intestinal ischemia-reperfusion; VEGF, 
vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.Available online http://ccforum.com/content/10/5/R130
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Redistributed VEGFR-2 expression in the injured lung 
tissues
The VEGFR-2 immunostaining in control and sham groups
revealed strong staining on bronchial epithelial cells (Table 2),
with occasional and weak staining of alveolar type II epithelial
cells, macrophages and vascular endothelial cells (Figure 4a).
In the IIR group, the staining was redistributed in the cyto-
plasm, with a granular-like appearance in the infiltrated mono-
nuclear cells in the interstitium. An increased number of
positively stained type II cells was also observed (Figure 4a).
However, the total number of positively stained cells in the
alveolar units did not significantly change (Figure 4b). No
change was observed in the bronchial epithelium and vascular
endothelium (Table 2).
We used western blotting to determine the protein levels of
VEGF and its receptors in lung tissue. Results from two ani-
mals are shown in Figure 4c as examples. When quantified
with densitometry, no statistical significance was found. We
also used real-time quantitative RT-PCR to measure the
mRNA levels of VEGF and its receptors. The results are also
not statistically significant (data not shown).
Correlations of VEGF and its receptors with lung injury 
and epithelial cell death
We then examined whether the VEGF concentration in the
BAL correlates with parameters related to vascular permeabil-
ity (Table 3). The VEGF level was significantly correlated with
the total protein concentration in the BAL fluid. A significant
correlation was also found between VEGF concentration and
total cell count. The differential cell counting further revealed
that VEGF was correlated positively with the percentage of
macrophages, but inversely with neutrophils (both percentage
and cell number) in the BAL (Table 3).
To verify if epithelial cell death was related to the down-regu-
lation of VEGF and VEGFR-1, TUNEL and cytokeratin double
staining was performed. An increased number of TUNEL-
cytokeratin double positive cells was found in the IIR group
(Figure 5a), which was statistically significant when quantified
and compared with the cell death in the control and sham
groups (Figure 5b). The number of VEGF positive cells in the
alveolar units was negatively correlated with the number of
TUNEL-cytokeratin positive cells (Rho = -0.87, p = 0.001; Fig-
ure 5c). Similarly, the number of VEGFR-1 positive cells was
negatively correlated with that of TUNEL-cytokeratin positive
cells (Rho = -0.74, p = 0.011; Figure 5d). No significant cor-
relation was found with the number of VEGFR-2 positive cells.
These results suggest that reduced VEGF and VEGFR-1
Figure 3
Reduced vascular endothelial growth factor receptor (VEGFR)-1 expression in the lung tissue Reduced vascular endothelial growth factor receptor (VEGFR)-1 expression in the lung tissue. (a) VEGFR-1 immunostaining (n = 4/group). Slides 
shown are representatives of each group (magnification 1,000×). Positively stained cells are in brown (examples are shown with arrowheads). (b) 
Quantification of VEGFR-1 positive cells per field. Ten fields were counted from each animal and four animals from each group. The number of pos-
itive staining cells in the alveolar walls was decreased in the sham group, and further reduced in the intestinal ischemia reperfusion (IIR) group. *p < 
0.05 and **p < 0.01 compared with the control group.Critical Care    Vol 10 No 5    Mura et al.
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expression in lung tissue may contribute to the death of lung
epithelial cells.
Knock-down of either VEGF or VEGFR-1 reduced lung 
epithelial cell viability
To further determine the roles of VEGF and VEGFR-1 in lung
epithelial cell survival, human lung epithelial A549 cells were
pre-treated with pooled siRNAs that contain at least four
selected siRNA duplexes specifically against either human
VEGF or VEGFR-1. The specificity and efficacy of these siR-
NAs have been characterized by the manufacturer. In compar-
ison with the non-specific duplex RNA control, reduced cell
number and changes in cell morphology was observed (Figure
6a), and a significant reduction in cell viability (Figure 6b; p <
0.01) was detected by XTT assay at 24 hours after either
VEGF or VEGFR-1 siRNA treatment. The protein levels of
Figure 4
Intestinal ischemia reperfusion (IIR)-induced changes of vascular endothelial growth factor receptor (VEGFR)-2 in the lung tissue and immunoblot- ting of VEGF and its receptors Intestinal ischemia reperfusion (IIR)-induced changes of vascular endothelial growth factor receptor (VEGFR)-2 in the lung tissue and immunoblot-
ting of VEGF and its receptors. (a) VEGFR-2 immunostaining (four animals per group). Slides (magnification 1,000×) shown are representatives of 
indicated groups. Positively stained cells are in brown (examples are indicated with arrowheads). In the IIR group, some of the positive cells appear 
to be interstitial monocytes with strong staining in the cytoplasm. (b) Quantification of VEGFR-2-positive cells per field. Ten fields were counted from 
each animal and four animals from each group. (c) Western blotting for VEGF and its receptors. Results from two animals per group are used as 
examples. The optical density of blot bands were quantified with desitometry and normalized to that of glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) as controls. No significant difference was found among these three groups.Available online http://ccforum.com/content/10/5/R130
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VEGF or VEGFR-1 were reduced by siRNA treatment, as con-
firmed by immunofluorescent staining (Figure 6c) and western
blotting (Figure 6d) with specific antibodies against VEGF or
VEGFR-1, respectively. The non-specific duplex RNA had no
effects on cell viability and protein levels of VEGF and VEGFR-
1 in comparison with non-treated control.
Discussion
The present study is a comprehensive report on the early
responses of VEGF and its receptors in an animal model of
ALI. We observed an increase of VEGF in the BAL, a
decreased expression of VEGF and VEGFR-1, and an altered
expression pattern of VEGFR-2 in the lung tissue. The VEGF
levels in BAL correlated with pulmonary permeability.
Decreased expression of VEGF and VEGFR-1 in the lung tis-
sue negatively correlated with death of alveolar epithelial cells.
Using cell culture as a model system, we further demonstrated
that VEGF and/or VEGFR-1 may play an important role in lung
epithelial cell survival.
The VEGF levels in the BAL were increased in both sham and
IIR groups, which suggests that these changes may be related
to hyperoxia and/or MV, applied to animals in both groups [32-
34]. Although it is well known that hypoxia is the most potent
regulator of VEGF gene expression and protein production
[35], an oxygen-independent up-regulation of VEGF and vas-
cular barrier dysfunction has been observed [36]. A rise in
VEGF levels in the BAL in a chronic hyperoxia model in piglets
has also been reported [32]. This could be explained at least
partially by the release of VEGF from extracellular matrix
through hyperoxia-induced proteolytic cleavage [33,34].
Although animals in this study were ventilated with low tidal
volume, we cannot exclude the contribution of mechanical fac-
tors to the release of VEGF [37], or an addictive effect
between MV and hyperoxia.
Alveolar macrophages represent a potential source of VEGF in
ALI [16]. We found a positive correlation between the VEGF
levels and percentage of macrophages in the BAL. The gran-
ules in the neutrophils also contain VEGF and may represent
an additional source of VEGF [38]; however, proteases
released by these cells may cleave VEGF [39], which could
explain the negative correlation between VEGF levels and the
number or percentage of neutrophils in the BAL. The numbers
of observations in these correlation studies are small; thus,
these results should be interpreted with caution.
We noted a significant correlation of the VEGF concentrations
with the total protein concentrations and with the total cell
counts in the BAL. High concentrations of VEGF within the
lung may contribute to the development of pulmonary edema
by alternating the state of the adherens junction complexes on
the endothelium [40]. An alternative explanation for this corre-
lation is that the increased VEGF is simply the reflection of
increased protein leakage in the lung. In clinical studies,
increased VEGF in plasma [16], and decreased VEGF in epi-
thelial lining fluid [17], or BAL [18], were noted in ARDS
patients. The present study was limited to the first four hours
of observation, while these clinical studies were performed
within the first couple of days after ARDS developed. It is
known that C57BL6 mice are very susceptible to lung hyper-
oxic stress [41]. These confounding factors may explain the
differences between our observation and those of others. Fur-
ther investigation is required to address these questions.
Despite the increased levels of VEGF in the BAL, a decreased
expression of VEGF in the lung tissue, as revealed by the IHC
staining, was observed specifically in the IIR group. Factors
other than hyperoxia, such as IIR-induced acute inflammatory
response, should be responsible for this drop in VEGF. Down-
regulation of VEGF has been observed in the rat lungs after
four hours of lipopolysaccharide challenge [18]. A down-regu-
lation of VEGF, as well as VEGF receptors, was also found at
24 hours and 72 hours after lipopolysaccharide injection in the
mouse lungs [42].
Cell death is a common feature of ALI and ARDS, contributing
to the dysfunction of the alveolar-capillary barrier [6]. The role
of VEGF as a survival factor for endothelial cells is already well
established [43,44]. A correlation between the reduced VEGF
levels and endothelial cell death has been found in the lungs
of ARDS patients [45]. The function of VEGF in epithelial cells,
Table 3
Correlation of VEGF levels with protein concentrations and cell counts in bronchoalveolar lavage fluid.
n Rho p
Protein (µg/ml) 30 0.79 <0.0001
Total cells (× 105/ml) 30 0.62 0.0002
Macrophages (percent) 9 0.73 0.028
Macrophages (× 105/ml) 9 0.50 0.260
Neutrophils (percent) 9 -0.83 0.007
Neutrophils (× 105/ml) 9 -0.79 0.036Critical Care    Vol 10 No 5    Mura et al.
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however, is largely unknown. Recent evidence suggests that
VEGF could also be a survival factor for epithelial cells. VEGF
stimulated growth of fetal airway epithelial cells [46] and the
proliferation of renal epithelial cells [47]. In a rat model of
obliterative bronchiolitis, Krebs and colleagues [48] observed
that VEGF either directly promoted epithelial regeneration or
inhibited epithelial cell death. Tang and co-workers [49]
observed that a transient ablation of the gene encoding VEGF
in the lung was associated with an increased number of
TUNEL-positive cells in the alveolar walls. In the present study,
we found a negative correlation between the number of VEGF-
positive cells and TUNEL-positive epithelial cells. To further
determine the role of VEGF in lung epithelial cell survival, we
used siRNA to knock-down VEGF expression in A549 cells.
This technique has been successfully used to effectively and
specifically reduce the expression of other signal transduction
proteins in lung epithelial A549 cells [30] and other cell types
[29]. Our data show that the cell viability was significantly
reduced by siRNA for VEGF. Therefore, VEGF could be a sur-
vival factor for alveolar epithelial cells. On the other hand,
these cells are one of the main sources of VEGF in the lung
[11]. Thus, the death of alveolar epithelial cells could be par-
tially responsible for the decreased expression of VEGF [50].
VEGFR-1 is normally expressed on epithelial and endothelial
cells in the lung [23,51]. Compared with VEGFR-2, the func-
tion of VEGFR-1 in the lung is less determined. In the present
study, IHC showed a significant decrease in the expression of
VEGFR-1 in both the sham and the IIR groups, suggesting that
hyperoxia and/or MV may suppress its expression. The
decreased expression level of VEGFR-1 was more significant
in the IIR group (p < 0.01). The significant negative correlation
Figure 5
Intestinal ischemia reperfusion (IIR)-induced alveolar epithelial cell death is negatively correlated with vascular endothelial growth factor (VEGF) and  vascular endothelial growth factor receptor (VEGFR)-1 expression Intestinal ischemia reperfusion (IIR)-induced alveolar epithelial cell death is negatively correlated with vascular endothelial growth factor (VEGF) and 
vascular endothelial growth factor receptor (VEGFR)-1 expression. (a) Double fluorescents staining TUNEL (red)-cytokeratin (green). An increased 
number of epithelial cells (in green) undergoing cell death (in red) was detected in the IIR group. Slides shown are representatives of four animals 
from each group. (b) Epithelial cell death index was quantified by TUNEL-cytokeratin double positive cells over cytokeratin positive cells of each field 
(ten fields were quantified from each animal); *p < 0.05 compared with the control group; #p < 0.05 compared with the sham group. (c) Relation-
ship between TUNEL-positive-epithelial cells and VEGF-positive cells. (d) Relationship between TUNEL-positive-epithelial cells and VEGFR-1-posi-
tive cells.Available online http://ccforum.com/content/10/5/R130
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between VEGFR-1 positive cells and epithelial cell death sug-
gests that down-regulation of VEGFR-1 may be due to epithe-
lial cell death. However, when we knocked down the VEGFR-
1 protein level with siRNA, the viability A549 of cells was sig-
nificantly reduced. This observation is intriguing. It suggests
that VEGF and VEGFR-1 may modulate survival of lung epithe-
lial cells in an autocrine fashion.
VEGFR-2, mainly located on endothelial cells, but also on epi-
thelial type II cells [23], is responsible for most of the known
functions of VEGF in the lung [12] and, in particular, is involved
in the anti-apoptotic properties of VEGF on endothelial cells
[43]. In the control and sham-operated animals, the strong
staining of VEGFR-2 was found mainly on cells located at the
corners of the alveolar space with the appearance of type II
pneumocytes and alveolar macrophages. In the IIR group, the
number of VEGFR-2 positive cells did not change significantly.
The morphological features of cells that expressed VEGFR-2,
however, suggest that some of them could be the interstitial
monocytes. The accumulation of VEGFR-2-positive inflamma-
tory cells was also noted in a model of Bleomycin-induced
lung injury [23]. Moreover, in the IIR group, the expression of
VEGFR-2 was localized mainly in the cytoplasm, which was
not noted in the other two groups. This phenomenon indicates
that the function of VEGFR-2 may be altered by the inflamma-
tory responses in the lung tissue. Further investigation with
double immunostaining and confocal microscopy may provide
more convincing evidence.
When using western blotting and real-time quantitative RT-
PCR to measure the protein and mRNA levels of VEGF and its
receptors, the results are not statistically significant. The
expression and distribution of these molecules are scattered in
the lung tissue. When total tissue lysates were used as sam-
ples for immunoblotting, or as sources for total RNA extraction,
the background from surrounding cells and tissues may mask
the changes of VEGF, or its receptors.
Conclusion
Our results suggest that significant and dynamic changes of
expression of VEGF and its receptors take place during IIR-
induced acute lung injury. A rapid release of VEGF into alveo-
lar space may occur as a consequence of hyperoxia and/or
MV. Released VEGF may partially contribute to the develop-
ment of non-cardiogenic pulmonary edema. VEGF and
VEGFR-1 may play important roles in maintaining alveolar epi-
thelial cell survival. Acute inflammatory responses and alveolar
epithelial injury may reduce their expression, which may subse-
Figure 6
Lung epithelial cell death induced by vascular endothelial growth factor (VEGF) or vascular endothelial growth factor receptor (VEGFR)-1 knock- down Lung epithelial cell death induced by vascular endothelial growth factor (VEGF) or vascular endothelial growth factor receptor (VEGFR)-1 knock-
down. Human A549 cells were cultured in 24-well plates and transfected with 50 nM of small interference RNA (siRNA) specifically against either 
VEGF or VEGFR-1, or with a non-specific duplex RNA (NS) as control for 24 h. (a) VEGF or VEGFR-1 siRNA induced changes in cell number and/
or cell morphology in A549 cells. Pictures shown are representatives for each treatment (magnification 400×). (b) XTT assay for cell viability. The 
data shown are mean ± standard deviation from three separated experiments. **p < 0.01 versus the non-specific control. (c) VEGF and VEGFR-1 
immunofluorescent staining at 24 h after treatment with different RNA duplexes. Decreased staining was noted in siRNA treated cells. (d) Western 
blots confirmed that siRNA specifically reduced VEGF or VEGFR-1 protein expression.Critical Care    Vol 10 No 5    Mura et al.
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quently lead to cell death. Alternatively, death of alveolar epi-
thelial cells may limit the production of VEGF in the lung.
Further investigation with more specific tools or transgenic
animals may elucidate the intricate role of VEGF system in
acute lung injury.
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